Literature DB >> 24285605

Early outcomes of alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a European multicenter and multinational study.

Josef Veselka1, Thorsten Lawrenz, Christoph Stellbrink, David Zemanek, Marian Branny, Jaroslav Januska, Jan Sitar, Pawel Dimitrow, Jan Krejci, Maciej Dabrowski, Stanislav Mizera, Thomas Bartel, Horst Kuhn.   

Abstract

BACKGROUND: This study was designed to evaluate the outcomes of alcohol septal ablation (ASA) under multicenter and multinational conditions.
METHODS: Data for 459 patients (age 57 ± 13 years) from nine European centers were prospectively collected and retrospectively analyzed.
RESULTS: ASA led to a significant reduction in outflow gradient (PG) and dyspnea [median of PG from 88 (58-123) mm Hg to 21 (11-41) mm Hg; median of NYHA class from 3 (2-3) to 1 (1-2); P < 0.01]. The incidence of 3-month major adverse events (death, electrical cardioversion for tachyarrhythmias, resuscitation) and mortality was 2.8% and 0.7%, respectively. Permanent pacemakers for post-ASA complete heart block were implanted in 43 patients (9%). Multivariate analysis identified higher amount of alcohol (however, in generally low-dose procedures), higher baseline left ventricular ejection fraction and higher age as independent predictors of PG decrease ≥50%.
CONCLUSIONS: The results of the first European multicenter and multinational study demonstrate that real-world early outcomes of ASA patients are better than was reported in observations from the first decade after ASA introduction.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  alcohol septal ablation; cardiomyopathy; hypertrophic cardiomyopathy

Mesh:

Substances:

Year:  2013        PMID: 24285605     DOI: 10.1002/ccd.25236

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  6 in total

1.  How to Treat Obstructions in Patients with Hypertrophic Cardiomyopathy.

Authors:  Josef Veselka
Journal:  Int J Angiol       Date:  2015-06

Review 2.  Current status and future perspectives on alcohol septal ablation for hypertrophic obstructive cardiomyopathy.

Authors:  Rami N Khouzam; Srihari S Naidu
Journal:  Curr Cardiol Rep       Date:  2014-05       Impact factor: 2.931

3.  Patients with hypertrophic obstructive cardiomyopathy after alcohol septal ablation have favorable long-term outcome irrespective of their genetic background.

Authors:  Jiří Bonaventura; Patricia Norambuena; Pavel Votýpka; Hana Hnátová; Radka Adlová; Milan Macek; Josef Veselka
Journal:  Cardiovasc Diagn Ther       Date:  2020-04

Review 4.  Obstructive Form of Hypertrophic Cardiomyopathy-Left Ventricular Outflow Tract Gradient: Novel Methods of Provocation, Monitoring of Biomarkers, and Recent Advances in the Treatment.

Authors:  Pawel Petkow Dimitrow; Renata Rajtar-Salwa
Journal:  Biomed Res Int       Date:  2016-05-10       Impact factor: 3.411

Review 5.  Intervention in HCM: patient selection, procedural approach and emerging techniques in alcohol septal ablation.

Authors:  Robert M Cooper; Adeel Shahzad; Rodney H Stables
Journal:  Echo Res Pract       Date:  2014-10-30

6.  Valsartan inhibits RhoA-ROCK2-MYL pathway in rat model of alcoholic cardiomyopathy.

Authors:  Luyifei Li; Ling Jing; Jiyi Zhao; Jiachen Lv; Wen Yang; Weimin Li; Lijun Zhou
Journal:  Exp Ther Med       Date:  2019-10-07       Impact factor: 2.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.